Bernard Coulie - 23 Jan 2025 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
President and CEO, Director
Signature
/s/ Jennifer Woo, attorney-in-fact
Issuer symbol
PLRX
Transactions as of
23 Jan 2025
Net transactions value
$0
Form type
4
Filing time
27 Jan 2025, 17:58:27 UTC
Previous filing
22 Jan 2025
Next filing
20 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Award $0 +162,500 +38% $0.000000 593,017 23 Jan 2025 Direct F1
holding PLRX Common Stock 409,317 23 Jan 2025 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLRX Stock Option (Right to Buy) Award $0 +325,000 $0.000000 325,000 23 Jan 2025 Common Stock 325,000 $11.14 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2 Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.